Glancy
Binkow & Goldberg LLP, representing investors of Catalyst
Pharmaceutical Partners, Inc. (“Catalyst” or the “Company”)
(NASDAQ:CPRX), announces that all purchasers of Catalyst securities
between October 31, 2012 and October 18, 2013, inclusive (the “Class
Period’) have until December 24, 2013, to file a motion to be appointed
as lead plaintiff in the shareholder lawsuit filed in the United States
District Court for the Southern District of Florida.
A COPY OF THE COMPLAINT
IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE
CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM
TO DISCUSS THIS MATTER. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR
MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.
Catalyst is a pharmaceutical company focused on developing and marketing
novel prescription drugs targeting rare neuromuscular and neurological
diseases and disorders. One of the Company’s principal products is
Firdapse, currently in Phase III clinical trials for treatment of
Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disease. The
Complaint alleges that defendants failed to disclose that a competitor
company has been manufacturing a drug equivalent to Firdapse, and
providing it to patients with LEMS, free of charge through a
compassionate use program, for the past 20 years. On October 18, 2013,
an article published by TheStreet alleged that Catalyst’s
Firdapse is the same drug that its competitor has been manufacturing and
providing in the U.S. for the past 20 years.
To learn
more about this action or if you have any questions concerning this
Notice or your rights or interests with respect to these matters, please
contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Copyright Business Wire 2013